Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors

Journal of Translational Medicine

Volumn 5, Issue , 2007, Pages

  Guida, Michele ^a   Casamassima, Addolorata ^a   Monticelli, Giulia ^a   Quaranta, Michele ^a   Colucci, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CYTOKINE; GEMCITABINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; NAVELBINE; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REFERENCE VALUE; SURVIVAL RATE; SURVIVAL TIME; ANALYSIS OF VARIANCE; BLOOD; INFLAMMATION; KIDNEY TUMOR; METABOLISM; METASTASIS; MORTALITY; NONPARAMETRIC TEST; PATHOLOGY; SURVIVAL;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CYTOKINES; HUMANS; INFLAMMATION; INTERLEUKIN-2; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; REFERENCE VALUES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37749004249     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-5-51     Document Type: Article

References (18)

1. Yagoda A Abi-Rached B Petrylak D Chemotherapy for advanced renal cell carcinoma, 1983-1993 Semin Oncol 1995, 22:42-60 7855619
2. Bleumer I Oosterevijk E De Mulder P Mulders PF Immunotherapy for renal cell carcinoma Eur Urol 2003, 44:65-75 10.1016/S0302-2838(03)00191-X 12814677
3. Negrier S Escudier B Lasset C Douillard JY Savary J Chevreau C Ravaud A Mercatello A Peny J Mousseau M Philip T Tursz T Recombinant human interleukin-2, recombinant human interferon alfa-2a or both in metastatic renal cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 1998, 338:1272-1288 10.1056/NEJM199804303381805 9562581
4. Atzpodien J Hoffmann R Franzke M Stief C Wandert T Reitz M Thirteen-year, long-term efficacy of interferon 2α and interleukin-2-based home therapy in patients with advanced renal cell carcinoma Cancer 2002, 95:1045-1050 10.1002/cncr.10783 12209689
5. Guida M Lorusso V De Lena M Di Tonno P Battaglia M Selvaggi FP Subcutaneous rIL-2 plus vinorelbine (VNB) and gemcitabine (GEM) in metastatic renal cell carcinoma [abstract]. American Society of Clinical Oncology meeting J Clin Oncol 2002, 2420
6. Motzer RJ Hutson TE Tomczak P Michaelson MD Bukowski RM Rixe O Oudard S Negrier S Szczylik C Kim ST Chen I Bycott PW baum CM Figlin RA Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma N Engl J Med 2007, 356:115-124 10.1056/NEJMoa065044 17215529
7. Escudier B Eisen T Stadler WM Szczylik C Oudard S Siebels M Negrier S Chevreau C Solska E Desai AA Rolland F Demkow t Hutson TE Gore M Freeman S Schwartz B Shan M Simantov R Bukowski RM TARGET Study Group Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma N Engl J Med 2007, 356:125-134 10.1056/NEJMoa060655 17215530
8. Atzpodien J Royston P Wandert T Reitz M DGCIN- German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group Metastatic renal carcinoma comprehensive prognostic system Br J Cancer 2003, 88:348-353 10.1038/ sj.bjc.6600768 12569375
9. Negrier S Escudier B Gomez F Douillard JY Ravaud A Chevreau C Buclon M Perol D Lasset C Prognostic factors of survival and rapid progression in 782 patinets with metastatic renal carcinomas treated by cytokines. A report from the Groupe Francais d'Immunotherapie Ann Oncol 2002, 13:1460-1468 10.1093/annonc/mdf257 12196373
10. Palmer PA Vinke J Philip T Negrier S Atzpodien J Kirchner H Oskam R Franks CR Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2 Ann Oncol 1992, 3:475-480 1498066
11. Motzer RJ Bacik J Mariani T Russo P Mazumdar M Reuter V Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology J Clin Oncol 2002, 20:2376-2381 10.1200/ JCO.2002.11.123 11981011
12. Feghali CA Wright TM Cytokines in acute and chronic inflammation Front Biosci 1997, 2:d12 Review. 9159205
13. Jason J Archibald LK Nwanyanwu OC Byrd MG Kazembe PN Dobbie H Jarvis WR Comparison of serum and cell-specific cytokines in humans Clin Diagn Lab Immunol 2001, 8(6):1097-1103 96232 11687446 10.1128/ CDLI.8.6.1097-1103.2001
14. Remick DG Friedland JS Cytokines in health and disease Marcel Dekker, Inc. New York 1997
15. Casamassima A Picciariello M Quaranta M Berardino R Ranieri C Paradiso A Lorusso V Guida M C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinonma treated with subcutaneous interleukin-2 based immunotherapy J Urology 2005, 174:2422-2433
16. Greenlee RT Hill-Harman MB Murray T Thun M Cancer statistics CA Cancer J Clin 2001, 51:15-36 11577478
17. Jin P Wang E Provenzano M Deola S Selleri S Ren J Voiculescu S Stroncek D Panelli M Marincola FM Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets J Transl Med 2006, 28:4-26
18. Guida M Riccobon A Biasco G Ravaioli A Casamassima A Freschi A Dalla Palma M Galligioni E Nortilli R Chiarion-Sileni V Picozzo J Romanini A Nanni O Ridolfi R Basal levels and behaviour of cytokines in a randomized autpatient trial comparing chemotherapy and immunochemotherapy in metastatic melanoma Mel Research 2006, 3:53-59